First Wave BioPharma, Inc. (FWBI)
| Market Cap | 22.27M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -39.68M |
| Shares Out | 7.81M |
| EPS (ttm) | -10.80 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 223,925 |
| Open | 2.87 |
| Previous Close | 2.87 |
| Day's Range | 2.78 - 2.91 |
| 52-Week Range | 2.61 - 26.30 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | Nov 15, 2021 |
About FWBI
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, specializes in the development of targeted, non-systemic therapies for gastrointestinal diseases. The company is advancing a therapeutic development pipeline populated with various clinical stage programs built around its two proprietary technologies, known as niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. Its niclosam...
Financial Performance
Financial StatementsNews
First Wave BioPharma Announces Two Additions to Scientific Advisory Board
Globally Recognized Experts in Gastrointestinal Diseases, Cystic Fibrosis and Virology to Support Company in Advancing Niclosamide and Adrulipase Clinical Programs Globally Recognized Experts in Gastroi...
AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today
Company to begin trading on Nasdaq under new ticker symbol, “FBWI”, effective September 22 Company to begin trading on Nasdaq under new ticker symbol, “FBWI”, effective September 22
3 Penny Stocks That Top Investors Buying Right Now
Which penny stocks are you watching in September 2021? Here's three for some watchlist inspiration The post 3 Penny Stocks That Top Investors Buying Right Now appeared first on Penny Stocks to Buy, Pick...
AzurRx (AZRX) Announces First Wave Bio Acquisition for $229M
AzurRx BioPharma (AZRX) acquires First Wave Bio for $229 million. Following the acquisition, the company is set to rename itself as First Wave BioPharma.
AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of Fir...
BOCA RATON, Fla., Sept. 14, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the devel...
AzurRx BioPharma Announces Reverse Merger With First Wave Bio
AzurRx BioPharma Inc (NASDAQ: AZRX) has agreed to acquire First Wave Bio Inc in a stock and cash transaction valued at $229 million, including milestone payments. First Wave Bio is a clinical-stage bio...
AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi...
AzurRx BioPharma to be renamed “First Wave BioPharma” and trade under new NASDAQ ticker symbol, “FWBI”
AzurRx BioPharma Announces Reverse Stock Split
Common Stock Will Begin Trading on Split-Adjusted Basis on September 13, 2021 Common Stock Will Begin Trading on Split-Adjusted Basis on September 13, 2021
AzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial Evaluating Niclosamide for t...
Phase 2 placebo-controlled clinical trial to confirm safety of FW-1022 and investigate its ability to remove SARS-CoV-2 virus from the GI tract Phase 2 placebo-controlled clinical trial to confirm safet...
AzurRx BioPharma Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Par...
Review of Interim Safety Data Concluded with Favorable Recommendation to Continue RESERVOIR Trial as Planned
AzurRx BioPharma Submits an Investigational New Drug Application for Niclosamide as Treatment for Grade 1 and Grade 2...
Proposed Phase 1b/2a clinical trial designed to determine safety and potential efficacy of oral and topical FW-420 Proposed Phase 1b/2a clinical trial designed to determine safety and potential efficacy...
AzurRx BioPharma to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference
BOCA RATON, Fla., Sept. 07, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies for ...
3 Penny Stocks That Top Investors Are Buying Right Now
Top traders are watching these penny stocks right now, here's why The post 3 Penny Stocks That Top Investors Are Buying Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | Pen...
AzurRx (AZRX) Pancreatic Insufficiency Study Meets Endpoints
AzurRx (AZRX) is developing lead pipeline candidate as monotherapy and in combination regimen as potential treatment for exocrine pancreatic insufficiency in patients with cystic fibrosis.
AZRX Stock: The Huge Trial News Lifting Little-Known AzurRX BioPharma Today
Today, AZRX stock is making headlines after the company showed some impressive results from a clinical trial of a cystic fibrosis treatment. The post AZRX Stock: The Huge Trial News Lifting Little-Known...
AzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Pati...
BOCA RATON, Fla., Aug. 18, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies for g...
AzurRx BioPharma Announces WHO Publication of “Adrulipase Alfa” as International Nonproprietary Name for MS1819
BOCA RATON, Fla., Aug. 17, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies for g...
AzurRx BioPharma Adds New Clinical Trial Sites in Ukraine for Phase 2 RESERVOIR Clinical Trial of Niclosamide for the...
BOCA RATON, Fla., Aug. 10, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, recombinant the...
New Strong Sell Stocks for August 5th
AZRX, GHL, HEES, LGND, and POLY have been added to the Zacks Rank #5 (Strong Sell) List on August 5, 2021.
AzurRx BioPharma Announces Closing of $5.75 Million Bought Deal Offering and Exercise in Full of Underwriter's Option...
BOCA RATON, Fla., July 27, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targ...
Biotech Penny Stocks Are Heating Up, Here's 3 To Watch Right Now
Why investors are watching these 3 biotech penny stocks right now The post Biotech Penny Stocks Are Heating Up, Here's 3 To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Informa...
AzurRx BioPharma Increases Previously Announced Bought Deal to $5.0 Million
BOCA RATON, Fla., July 22, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targ...
AzurRx BioPharma Announces $3.0 Million Bought Deal Offering of Common Stock
BOCA RATON, Fla., July 22, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targ...
AzurRx BioPharma CEO James Sapirstein to Present at 2021 BIO Digital
BOCA RATON, Fla., June 08, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targ...
AzurRx BioPharma to Present at Rocky Mountain Microcap Conference (May 26)
DELRAY BEACH, Fla., May 19, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of tar...